Search Results

MMI (Medical Microinstruments, Inc.) today announced the completion of its first clinical cases in the United States using the Symani® Surgical System.

MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that its Symani® Surgical System is now commercially available in the United States.

MMI, a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, announced that it has raised $110 million in Series C financing.

MMI (Medical Microinstruments, Inc.) today announced the company has been invited to participate in the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco.

MMI, a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, announced the successful completion of over 500 in-human surgeries with the Symani® Surgical System in the European Union.

MMI ( Medical Microinstruments, Inc. ), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California on January 9-12, 2023.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).